Specialized Medical Company (TADAWUL:4019)
Saudi Arabia
· Delayed Price · Currency is SAR 18.95
+0.25 (1.34%)
At close: Dec 4, 2025
TADAWUL:4019 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 1,460 | 1,440 | 1,368 | 1,209 | 1,053 | 867.24 |
| Revenue Growth (YoY) | -1.72% | 5.24% | 13.18% | 14.77% | 21.44% | - |
| Cost of Revenue | 1,117 | 1,055 | 1,019 | 930 | 824.89 | 704.07 |
| Gross Profit | 342.93 | 384.85 | 348.96 | 278.66 | 228.24 | 163.16 |
| Selling, General & Admin | 148.51 | 154.55 | 134.38 | 150.91 | 159.04 | 108.12 |
| Operating Expenses | 148.51 | 154.55 | 134.38 | 150.91 | 159.04 | 108.12 |
| Operating Income | 194.41 | 230.3 | 214.58 | 127.75 | 69.2 | 55.05 |
| Interest Expense | -43.04 | -44.98 | -48.46 | -29.82 | -18.89 | -15.39 |
| Other Non Operating Income (Expenses) | 17.07 | 10.62 | 8.52 | 9.13 | 8.98 | 8.13 |
| EBT Excluding Unusual Items | 168.44 | 195.95 | 174.65 | 107.05 | 59.29 | 47.79 |
| Gain (Loss) on Sale of Assets | -2.29 | -2.29 | 0.05 | 0.06 | - | - |
| Pretax Income | 166.14 | 193.66 | 174.7 | 107.12 | 59.29 | 47.79 |
| Income Tax Expense | 7.74 | 8.44 | 6 | 4.15 | 3.32 | 1.77 |
| Net Income | 158.4 | 185.22 | 168.7 | 102.96 | 55.97 | 46.02 |
| Net Income to Common | 158.4 | 185.22 | 168.7 | 102.96 | 55.97 | 46.02 |
| Net Income Growth | -27.36% | 9.79% | 63.84% | 83.97% | 21.62% | - |
| Shares Outstanding (Basic) | 250 | 250 | 85 | 85 | 9 | 9 |
| Shares Outstanding (Diluted) | 250 | 250 | 85 | 85 | 9 | 9 |
| Shares Change (YoY) | 19.76% | 194.12% | - | 900.00% | - | - |
| EPS (Basic) | 0.63 | 0.74 | 1.98 | 1.21 | 6.58 | 5.41 |
| EPS (Diluted) | 0.63 | 0.74 | 1.98 | 1.21 | 6.58 | 5.41 |
| EPS Growth | -39.34% | -62.67% | 63.84% | -81.60% | 21.62% | - |
| Free Cash Flow | 329.45 | 289.52 | 160.53 | 116.6 | -159.38 | -2.68 |
| Free Cash Flow Per Share | 1.32 | 1.16 | 1.89 | 1.37 | -18.75 | -0.32 |
| Gross Margin | 23.48% | 26.73% | 25.51% | 23.05% | 21.67% | 18.81% |
| Operating Margin | 13.31% | 16.00% | 15.69% | 10.57% | 6.57% | 6.35% |
| Profit Margin | 10.85% | 12.87% | 12.33% | 8.52% | 5.31% | 5.31% |
| Free Cash Flow Margin | 22.56% | 20.11% | 11.73% | 9.65% | -15.13% | -0.31% |
| EBITDA | 257.08 | 288.77 | 273.08 | 202.59 | 141.55 | 110.46 |
| EBITDA Margin | 17.60% | 20.06% | 19.96% | 16.76% | 13.44% | 12.74% |
| D&A For EBITDA | 62.66 | 58.47 | 58.49 | 74.85 | 72.35 | 55.42 |
| EBIT | 194.41 | 230.3 | 214.58 | 127.75 | 69.2 | 55.05 |
| EBIT Margin | 13.31% | 16.00% | 15.69% | 10.57% | 6.57% | 6.35% |
| Effective Tax Rate | 4.66% | 4.36% | 3.44% | 3.88% | 5.60% | 3.70% |
Source: S&P Capital IQ. Standard template. Financial Sources.